Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2021-01-34283,2021,Yoon 2021 Plast Reconstr Surg,2100,volar locking plate VERSUS external fixation IN Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,33235040,Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,volar locking plate,Cost-Effectiveness of Treatments after Closed Extraarticular Distal Radius Fractures  in Older Adults from the WRIST Clinical Trial.,external fixation,NE
2021-01-34283,2021,Yoon 2021 Plast Reconstr Surg,29000,closed reduction percutaneous pinning VERSUS Standard/Usual Care- casting IN Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,33235040,Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,closed reduction percutaneous pinning,Cost-Effectiveness of Treatments after Closed Extraarticular Distal Radius Fractures  in Older Adults from the WRIST Clinical Trial.,Standard/Usual Care- casting,NE
2021-01-34283,2021,Yoon 2021 Plast Reconstr Surg,Dominated,external fixation VERSUS closed-reduction percutaneous pinning IN Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,33235040,Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,external fixation,Cost-Effectiveness of Treatments after Closed Extraarticular Distal Radius Fractures  in Older Adults from the WRIST Clinical Trial.,closed-reduction percutaneous pinning,NW
2021-01-34283,2021,Yoon 2021 Plast Reconstr Surg,Dominated,external fixation VERSUS Standard/Usual Care- casting IN Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,33235040,Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,external fixation,Cost-Effectiveness of Treatments after Closed Extraarticular Distal Radius Fractures  in Older Adults from the WRIST Clinical Trial.,Standard/Usual Care- casting,NW
2021-01-34283,2021,Yoon 2021 Plast Reconstr Surg,Dominated,volar locking plate VERSUS closed reduction percutaneous pinning IN Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,33235040,Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,volar locking plate,Cost-Effectiveness of Treatments after Closed Extraarticular Distal Radius Fractures  in Older Adults from the WRIST Clinical Trial.,closed reduction percutaneous pinning,NW
2021-01-34283,2021,Yoon 2021 Plast Reconstr Surg,Dominated,volar locking plate VERSUS Standard/Usual Care- casting IN Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,33235040,Specific disease- distal radius fracture; Age- >=65 years; Gender- Both; Country- United States.,volar locking plate,Cost-Effectiveness of Treatments after Closed Extraarticular Distal Radius Fractures  in Older Adults from the WRIST Clinical Trial.,Standard/Usual Care- casting,NW
2021-01-34282,2021,Bloudek 2021 J Med Econ,88000,topical glycopyrronium tosylate VERSUS topical aluminum chloride IN Specific disease- primary axillary hyperhidrosis; Age- 0 to 18 years; Gender- Both; Country- United States; Other- HDSS score of 3 or 4.,33256494,Specific disease- primary axillary hyperhidrosis; Age- 0 to 18 years; Gender- Both; Country- United States; Other- HDSS score of 3 or 4.,topical glycopyrronium tosylate,Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary  axillary hyperhidrosis.,topical aluminum chloride,NE
2021-01-34276,2021,Lester-Coll 2021 JAMA Netw Open,Cost-Saving,androgen deprivation therapy + prostate radiation therapy VERSUS Standard/Usual Care- androgen deprivation therapy IN Specific disease- metastatic prostate cancer; Age- >=65 years; Gender- Male; Country- United States.,33439266,Specific disease- metastatic prostate cancer; Age- >=65 years; Gender- Male; Country- United States.,androgen deprivation therapy + prostate radiation therapy,Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed  Low-Burden Metastatic Prostate Cancer.,Standard/Usual Care- androgen deprivation therapy,SE
2021-01-34270,2021,Shrestha 2021 Am J Prev Med,Cost-Saving,tips from former smokers tobacco education campaign VERSUS None IN Specific disease- smoking; Age- Adult; Gender- Both; Country- United States.,33455819,Specific disease- smoking; Age- Adult; Gender- Both; Country- United States.,tips from former smokers tobacco education campaign,"Cost Effectiveness of the Tips From Former Smokers® Campaign-U.S., 2012-2018.",None,SE
2021-01-34269,2021,Patel 2021 JAMA Netw Open,530000,encorafenib + cetuximab VERSUS Standard/Usual Care- cetuximab + irinotecan or cetuximab + folinic acid + fluorouracil + irinotecan IN Specific disease- colorectal cancer; Age- Adult; Gender- Both; Country- United States; Other- BRAF Variant .,33433598,Specific disease- colorectal cancer; Age- Adult; Gender- Both; Country- United States; Other- BRAF Variant .,encorafenib + cetuximab,Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant  Colorectal Cancer.,Standard/Usual Care- cetuximab + irinotecan or cetuximab + folinic acid + fluorouracil + irinotecan,NE
2021-01-34235,2021,Chiang 2021 JAMA Netw Open,340000,pembrolizumab VERSUS Placebo IN Specific disease- liver cancer; Age- Adult; Gender- Both; Country- United States; Other- previously treated with sorafenib.,33464318,Specific disease- liver cancer; Age- Adult; Gender- Both; Country- United States; Other- previously treated with sorafenib.,pembrolizumab,Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular  Carcinoma.,Placebo,NE
2021-01-34185,2021,Ding 2021 Oncologist,150000,pembrolizumab + axitinib VERSUS sunitinib IN Specific disease- renal cancer; Age- Adult; Gender- Both; Country- United States.,32918790,Specific disease- renal cancer; Age- Adult; Gender- Both; Country- United States.,pembrolizumab + axitinib,Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line  Therapy in Advanced Renal Cell Carcinoma in the U.S.,sunitinib,NE
2021-01-34054,2021,Kawakami 2021 Am Heart J,11000,left atrial appendage closure strategy VERSUS Standard/Usual Care- oral anticoagulation strategy IN Specific disease- atrial fibrillation; Age- >=65 years; Gender- Both; Country- United States; Other- high thrombotic and bleeding risk.,32822655,Specific disease- atrial fibrillation; Age- >=65 years; Gender- Both; Country- United States; Other- high thrombotic and bleeding risk.,left atrial appendage closure strategy,Cost-effectiveness of combined catheter ablation and left atrial appendage closure  for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.,Standard/Usual Care- oral anticoagulation strategy,NE
2020-01-36167,2020,Verma 2020 Proc Natl Acad Sci U S A,40000,long-acting direct-acting antiviral system VERSUS Standard/Usual Care- direct-acting antiviral alone IN Specific disease- hepatitis c; Age- 19 to 40 years; Gender- Male; Country- United States.,32424082,Specific disease- hepatitis c; Age- 19 to 40 years; Gender- Male; Country- United States.,long-acting direct-acting antiviral system,Development of a long-acting direct-acting antiviral system for hepatitis C virus  treatment in swine.,Standard/Usual Care- direct-acting antiviral alone,NE
2020-01-36046,2020,Cook 2020 J Med Econ,Cost-Saving,valoctocogene roxaparvovec VERSUS Standard/Usual Care- prophylaxis IN Specific disease- hemophilia a; Age- Adult; Gender- Both; Country- United States.,31971453,Specific disease- hemophilia a; Age- Adult; Gender- Both; Country- United States.,valoctocogene roxaparvovec,Assessing the potential cost-effectiveness of a gene therapy for the treatment of  hemophilia A.,Standard/Usual Care- prophylaxis,SE
2020-01-35483,2020,Su 2020 Orthop J Sports Med,32000,operative treatment VERSUS nonoperative treatment IN Specific disease- acute achilles tendon ruptures; Age- Adult; Gender- Both; Country- United States.,32284940,Specific disease- acute achilles tendon ruptures; Age- Adult; Gender- Both; Country- United States.,operative treatment,Operative Versus Nonoperative Treatment of Acute Achilles Tendon Ruptures: A Pilot  Economic Decision Analysis.,nonoperative treatment,NE
2020-01-35378,2020,Fuller 2020 J Diabetes Sci Technol,260000,"automated retinal image analysis systems based screening for diabetic retinopathy VERSUS Standard/Usual Care- dilated retinal examination IN Specific disease- diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- low income, primary care clinic setting.",33124449,"Specific disease- diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- low income, primary care clinic setting.",automated retinal image analysis systems based screening for diabetic retinopathy,"Five-Year Cost-Effectiveness Modeling of Primary Care-Based, Nonmydriatic Automated  Retinal Image Analysis Screening Among Low-Income Patients with Diabetes.",Standard/Usual Care- dilated retinal examination,SW
2020-01-35354,2020,Hiligsmann 2020 Semin Arthritis Rheum,130000,"abaloparatide --> alendronate VERSUS alendronate (5 years) IN Healthy; Age- >=65 years; Gender- Female; Country- United States; Other- increased fracture risk, bone mineral density T-score >-3.5 and <-2.5, at least 1 osteoporotic fracture, postmenopausal.",32160943,"Healthy; Age- >=65 years; Gender- Female; Country- United States; Other- increased fracture risk, bone mineral density T-score >-3.5 and <-2.5, at least 1 osteoporotic fracture, postmenopausal.",abaloparatide --> alendronate,Cost-effectiveness of sequential treatment with abaloparatide followed by  alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US  payer perspective.,alendronate (5 years),NE
2020-01-35354,2020,Hiligsmann 2020 Semin Arthritis Rheum,75000,"abaloparatide --> alendronate VERSUS alendronate (5 years) IN Healthy; Age- >=65 years; Gender- Female; Country- United States; Other- increased fracture risk, bone mineral density T-score <=-3.5, no fracture history, postmenopausal.",32160943,"Healthy; Age- >=65 years; Gender- Female; Country- United States; Other- increased fracture risk, bone mineral density T-score <=-3.5, no fracture history, postmenopausal.",abaloparatide --> alendronate,Cost-effectiveness of sequential treatment with abaloparatide followed by  alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US  payer perspective.,alendronate (5 years),NE
2020-01-35354,2020,Hiligsmann 2020 Semin Arthritis Rheum,Cost-Saving,"abaloparatide --> alendronate VERSUS alendronate (2 years) --> abaloparatide (18 months) --> alendronate (3 years) IN Healthy; Age- >=65 years; Gender- Female; Country- United States; Other- increased fracture risk, bone mineral density T-score <=-3.5, no fracture history, postmenopausal.",32160943,"Healthy; Age- >=65 years; Gender- Female; Country- United States; Other- increased fracture risk, bone mineral density T-score <=-3.5, no fracture history, postmenopausal.",abaloparatide --> alendronate,Cost-effectiveness of sequential treatment with abaloparatide followed by  alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US  payer perspective.,alendronate (2 years) --> abaloparatide (18 months) --> alendronate (3 years),SE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
